Agilent Technologies (NYSE:A)‘s stock had its “buy” rating reiterated by equities research analysts at Robert W. Baird in a report released on Thursday, January 18th. They presently have a $76.00 target price on the medical research company’s stock. Robert W. Baird’s price objective points to a potential upside of 13.47% from the stock’s previous close.
A number of other research analysts have also weighed in on A. Zacks Investment Research raised Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 price objective on the stock in a report on Tuesday, October 31st. Cowen reissued a “hold” rating and issued a $70.00 target price on shares of Agilent Technologies in a report on Wednesday, November 22nd. Deutsche Bank set a $75.00 price objective on Agilent Technologies and gave the company a “buy” rating in a research note on Tuesday, November 21st. JPMorgan Chase & Co. increased their price objective on Agilent Technologies to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, November 21st. Finally, Evercore ISI began coverage on Agilent Technologies in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $75.00 price objective on the stock. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Agilent Technologies presently has an average rating of “Buy” and an average price target of $69.25.
Shares of Agilent Technologies (NYSE:A) traded up $1.94 during trading on Thursday, hitting $66.98. The stock had a trading volume of 4,520,000 shares, compared to its average volume of 2,016,089. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.85 and a current ratio of 3.30. The firm has a market capitalization of $21,635.75, a P/E ratio of 31.90, a PEG ratio of 2.02 and a beta of 1.28. Agilent Technologies has a 1-year low of $50.02 and a 1-year high of $75.00.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 43,703 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $70.00, for a total transaction of $3,059,210.00. Following the transaction, the chief executive officer now owns 302,837 shares of the company’s stock, valued at approximately $21,198,590. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Didier Hirsch sold 12,964 shares of the stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $69.00, for a total value of $894,516.00. Following the completion of the transaction, the chief financial officer now directly owns 184,851 shares in the company, valued at approximately $12,754,719. The disclosure for this sale can be found here. Insiders sold 219,991 shares of company stock valued at $15,468,795 in the last ninety days.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. grew its stake in shares of Agilent Technologies by 8.1% in the fourth quarter. BlackRock Inc. now owns 25,665,358 shares of the medical research company’s stock worth $1,718,808,000 after purchasing an additional 1,912,186 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Agilent Technologies by 3.0% during the second quarter. Vanguard Group Inc. now owns 22,093,669 shares of the medical research company’s stock valued at $1,310,374,000 after purchasing an additional 637,698 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Agilent Technologies by 8.2% during the third quarter. Victory Capital Management Inc. now owns 3,330,488 shares of the medical research company’s stock valued at $213,817,000 after purchasing an additional 253,250 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Agilent Technologies by 5.8% during the fourth quarter. Wells Fargo & Company MN now owns 2,311,198 shares of the medical research company’s stock valued at $154,781,000 after purchasing an additional 126,696 shares during the period. Finally, Impax Asset Management LTD raised its holdings in shares of Agilent Technologies by 14.9% during the third quarter. Impax Asset Management LTD now owns 2,106,322 shares of the medical research company’s stock valued at $135,226,000 after purchasing an additional 272,571 shares during the period.
COPYRIGHT VIOLATION WARNING: This report was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://stocknewstimes.com/2018/02/11/agilent-technologies-a-given-buy-rating-at-robert-w-baird.html.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.